Dopamine agonist therapy for hyperprolactinemia

Brandon J. Bankowski, Howard A Zacur

Research output: Contribution to journalArticle

Abstract

Hyperprolactinemia significantly impairs the normal functioning of the reproductive system in women by its detrimental effects on gonadotropin secretion, ovarian follicular development, oocyte release, and corpus luteum function. Fortunately, hyperprolactinemia and the infertility that frequently accompanies it respond well to treatment with dopamine agonists, which inhibit pituitary prolactin release and thereby restore normal reproductive function. In addition, dopamine agonists usually facilitate the return of regular ovulatory menstrual cyclicity. Bromocriptine and cabergoline, the two dopamine agonists most commonly used for first-line treatment of hyperprolactinemia, have demonstrated efficacy even in the presence of pituitary adenomas. Cabergoline, with its improved tolerability, or other dopamine agonist alternatives may be used in patients who are intolerant of or resistant to bromocriptine. In amenorrheic, hyperprolactinemic women who desire to become pregnant, bromocriptine should be prescribed. However, women who are taking a long-acting dopamine agonist should discontinue the medication 1 month before trying to conceive.

Original languageEnglish (US)
Pages (from-to)349-362
Number of pages14
JournalClinical Obstetrics and Gynecology
Volume46
Issue number2
DOIs
StatePublished - Jun 2003

Fingerprint

Hyperprolactinemia
Dopamine Agonists
Bromocriptine
Therapeutics
Corpus Luteum
Pituitary Neoplasms
Periodicity
Gonadotropins
Prolactin
Infertility
Oocytes

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Dopamine agonist therapy for hyperprolactinemia. / Bankowski, Brandon J.; Zacur, Howard A.

In: Clinical Obstetrics and Gynecology, Vol. 46, No. 2, 06.2003, p. 349-362.

Research output: Contribution to journalArticle

Bankowski, Brandon J. ; Zacur, Howard A. / Dopamine agonist therapy for hyperprolactinemia. In: Clinical Obstetrics and Gynecology. 2003 ; Vol. 46, No. 2. pp. 349-362.
@article{267b620a00e64dcc9b82b3af9ce611a4,
title = "Dopamine agonist therapy for hyperprolactinemia",
abstract = "Hyperprolactinemia significantly impairs the normal functioning of the reproductive system in women by its detrimental effects on gonadotropin secretion, ovarian follicular development, oocyte release, and corpus luteum function. Fortunately, hyperprolactinemia and the infertility that frequently accompanies it respond well to treatment with dopamine agonists, which inhibit pituitary prolactin release and thereby restore normal reproductive function. In addition, dopamine agonists usually facilitate the return of regular ovulatory menstrual cyclicity. Bromocriptine and cabergoline, the two dopamine agonists most commonly used for first-line treatment of hyperprolactinemia, have demonstrated efficacy even in the presence of pituitary adenomas. Cabergoline, with its improved tolerability, or other dopamine agonist alternatives may be used in patients who are intolerant of or resistant to bromocriptine. In amenorrheic, hyperprolactinemic women who desire to become pregnant, bromocriptine should be prescribed. However, women who are taking a long-acting dopamine agonist should discontinue the medication 1 month before trying to conceive.",
author = "Bankowski, {Brandon J.} and Zacur, {Howard A}",
year = "2003",
month = "6",
doi = "10.1097/00003081-200306000-00013",
language = "English (US)",
volume = "46",
pages = "349--362",
journal = "Clinical Obstetrics and Gynecology",
issn = "0009-9201",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Dopamine agonist therapy for hyperprolactinemia

AU - Bankowski, Brandon J.

AU - Zacur, Howard A

PY - 2003/6

Y1 - 2003/6

N2 - Hyperprolactinemia significantly impairs the normal functioning of the reproductive system in women by its detrimental effects on gonadotropin secretion, ovarian follicular development, oocyte release, and corpus luteum function. Fortunately, hyperprolactinemia and the infertility that frequently accompanies it respond well to treatment with dopamine agonists, which inhibit pituitary prolactin release and thereby restore normal reproductive function. In addition, dopamine agonists usually facilitate the return of regular ovulatory menstrual cyclicity. Bromocriptine and cabergoline, the two dopamine agonists most commonly used for first-line treatment of hyperprolactinemia, have demonstrated efficacy even in the presence of pituitary adenomas. Cabergoline, with its improved tolerability, or other dopamine agonist alternatives may be used in patients who are intolerant of or resistant to bromocriptine. In amenorrheic, hyperprolactinemic women who desire to become pregnant, bromocriptine should be prescribed. However, women who are taking a long-acting dopamine agonist should discontinue the medication 1 month before trying to conceive.

AB - Hyperprolactinemia significantly impairs the normal functioning of the reproductive system in women by its detrimental effects on gonadotropin secretion, ovarian follicular development, oocyte release, and corpus luteum function. Fortunately, hyperprolactinemia and the infertility that frequently accompanies it respond well to treatment with dopamine agonists, which inhibit pituitary prolactin release and thereby restore normal reproductive function. In addition, dopamine agonists usually facilitate the return of regular ovulatory menstrual cyclicity. Bromocriptine and cabergoline, the two dopamine agonists most commonly used for first-line treatment of hyperprolactinemia, have demonstrated efficacy even in the presence of pituitary adenomas. Cabergoline, with its improved tolerability, or other dopamine agonist alternatives may be used in patients who are intolerant of or resistant to bromocriptine. In amenorrheic, hyperprolactinemic women who desire to become pregnant, bromocriptine should be prescribed. However, women who are taking a long-acting dopamine agonist should discontinue the medication 1 month before trying to conceive.

UR - http://www.scopus.com/inward/record.url?scp=0038826132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038826132&partnerID=8YFLogxK

U2 - 10.1097/00003081-200306000-00013

DO - 10.1097/00003081-200306000-00013

M3 - Article

C2 - 12808385

AN - SCOPUS:0038826132

VL - 46

SP - 349

EP - 362

JO - Clinical Obstetrics and Gynecology

JF - Clinical Obstetrics and Gynecology

SN - 0009-9201

IS - 2

ER -